Hepoxilin-epoxide hydrolase

hepoxilin-epoxide hydrolase
Identifiers
EC number 3.3.2.7
CAS number 122096-98-4
Databases
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum
Gene Ontology AmiGO / EGO

In enzymology, a hepoxilin-epoxide hydrolase (EC 3.3.2.7) is an enzyme that catalyzes the conversion of the epoxyalcohol metabolites arachidonic acid, hepoxilinA3 and hepoxilin B3 to their tri-hydroxyl products, trioxolin A3 and trioxilin B3, respectively. These reactions in general inactivate the two biologically active hepoxilins.[1]

Enzyme activity

Hepoxilin-epoxide hydrolase coverts the epoxide residue in hepoxilins A3 and B3 to Vicinal (chemistry) diols as exemplified in the following enzyme reaction for the metabolism of hepoxilin A3 to trioxilin A3:

8-hydroxy-11S,12Sepoxy-(5Z,8Z,14Z)-eicosatrienoic acid + H2O \rightleftharpoons 8,11,12-trihydroxy-(5Z,9E,14Z)-eicosatrienoic acid

The substrates of this enzyme are 8-hydroxy-11S,12Sepoxy-(5Z,8Z,14Z)-eicosatrienoic acid, i.e. hepoxilin A3 and H2O, whereas its product is 8,11,12-trihydroxy-(5Z,9E,14Z)-eicosatrienoic acid, i.e. the triol, trioxilin A3.[2]

Epoxide hydrolases

Epoxide hydrolases represent a group of enzymes that convert various types of epoxides to vicinal diols. Several members of this group have this metabolic activity on fatty acid epoxides including microsomal epoxide hydrolase (i.e. epoxide hydrolase 1 or EH1), soluble epoxide hydrolase (i.e. epoxide hydrolase 2 or EH2), epoxide hydrolase 3 (EH3), epoxide hydrolase 4 (EH4), and leukotriene A4 hydrolase (see epoxide hydrolase). The systematic name of this enzyme class is (5Z,9E,14Z)-(8xi,11R,12S)-11,12-epoxy-8-hydroxyicosa-5,9,14-trienoat e hydrolase. Other names in common use include hepoxilin epoxide hydrolase, hepoxylin hydrolase, and hepoxilin A3 hydrolase. Since the hepoxilins are metabolites of arachidonic acid, hepoxilin-epoxide hydrolase participates in arachidonic acid metabolism.

Identity of hepoxilin-epoxide hydrolase

Recent studies have shown that Soluble epoxide hydrolase (i.e. epoxide hydrolase 2 or EH2) readily metabolizes a) hepoxilin A3 (8-hydroxy-11S,12Sepoxy-(5Z,8Z,14Z)-eicosatrienoic acid) to trioxilin A3 (8,11,12-trihydroxy-(5Z,9E,14Z)-eicosatrienoic acid) and b) hepoxilin B3 (10-hydroxy-11S,12Sepoxy-(5Z,9E,14Z)-eicosatrienoic acid) to trioxlin B3 (10,11,12-trihydroxy-(5Z,9E,14Z)-eicosatrienoic acid. Soluble epoxide hydrolase (i.e. epoxide hydrolase 2 or EH2) sEH also appears to be the hepoxilin hydrolase that is responsible for inactivating the epoxyalcohol metabolites of arachidonic acid, hepoxilin A3 and hepoxiin B3. Soluble epoxide hydrolase is widely expressed in a diversity of human and other mammal tissues and therefore appears to be the hepoxilin hydrolase responsible for inactivating hepoxilin A3 and B3 (see soluble epoxide hydrolase#Function and epoxide hydrolase#Hepoxilin-epoxide hydrolase).[3][4] The ability of EH1, EH3, EH4, and leukotriene A4 hydrolase to metabolize hepoxilins to trioxilins has not yet been reported.

Function

Hepoxilins possess several activities (see hepoxilin#Physiological effect)[5] whereas their trioxilin products are generally considered to be inactive.[6] Accordingly, the soluble epoxide hydrolase metabolic pathway is considered to function in vivo to inactivate or limit the activity of the hepoxilins.[7][8][9][10] It should be emphasized, however, that the other fatty acid epoxide hydrolases cited in the Epoxide hydrolases section (above) have not be reported for hepoxilin-epoxide hydrolase activity, could possibly exhibit this, and therefore contribute to inactivating the hepoxilins.

References

  1. Biochim Biophys Acta. 2015 Apr;1851(4):383-96. doi: 10.1016/j.bbalip.2014.09.007. Epub 2014 Sep 19. Review.PMID: 25240838
  2. Biochim Biophys Acta. 2015 Apr;1851(4):383-96. doi: 10.1016/j.bbalip.2014.09.007. Epub 2014 Sep 19. Review.PMID: 25240838
  3. J Lipid Res. 2011 Apr;52(4):712-9. doi: 10.1194/jlr.M009639. Epub 2011 Jan 7.PMID: 21217101
  4. Biochim Biophys Acta. 2015 Apr;1851(4):383-96. doi: 10.1016/j.bbalip.2014.09.007. Epub 2014 Sep 19. Review.PMID: 25240838
  5. Br J Pharmacol. 2009 Oct;158(4):972-81. doi: 10.1111/j.1476-5381.2009.00168.x. Epub 2009 Apr 30. Review.PMID: 19422397
  6. Biochim Biophys Acta. 2015 Apr;1851(4):383-96. doi: 10.1016/j.bbalip.2014.09.007. Epub 2014 Sep 19. Review.PMID: 25240838
  7. Br J Pharmacol. 2009 Oct;158(4):972-81. doi: 10.1111/j.1476-5381.2009.00168.x. Epub 2009 Apr 30. Review.PMID: 19422397
  8. Biochim Biophys Acta. 2014 Mar;1841(3):401-8. doi: 10.1016/j.bbalip.2013.08.020. Epub 2013 Sep 7. Review.PMID: 24021977
  9. Biochim Biophys Acta. 2014 Mar;1841(3):401-8. doi: 10.1016/j.bbalip.2013.08.020. Epub 2013 Sep 7. ReviewPMID: 24021977
  10. Biochim Biophys Acta. 2015 Apr;1851(4):383-96. doi: 10.1016/j.bbalip.2014.09.007. Epub 2014 Sep 19. Review.PMID: 25240838
This article is issued from Wikipedia - version of the Tuesday, May 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.